Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01682083 · OUTCOME

Overall Survival (OS)

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
Approximately 10 years

What was measured

Overall Survival (OS) was defined as the interval from randomization to the date of death, irrespective of the cause of death. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.

Analysis population: Intent-to-Treat (ITT) Population

Groups in this outcome

Dabrafenib and Trametinib Combination Therapy

Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.

Dabrafenib and Trametinib Placebos

Subjects received matching placebos orally for 12 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dabrafenib and Trametinib Combination Therapy438
Dabrafenib and Trametinib Placebos432

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dabrafenib and Trametinib Combination TherapyNANot reported120.7NAN/A: Not Estimable due to number of events censored
Dabrafenib and Trametinib PlacebosNANot reportedNANAN/A: Not Estimable due to number of events censored

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.62
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.01
    group Description
    Hazard ratio is obtained from the stratified Pike estimator.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Comment
    A hazard ratio \<1 indicates a lower risk with dabrafenib + trametinib compared with Placebo.
    non Inferiority Type
    SUPERIORITY
    p Value
    0.063
    param Type
    Hazard Ratio, log
    param Value
    0.80
    statistical Comment
    Hazard Ratio and p-value from stratified log-rank test are adjusted for randomized strata: Disease stage and BRAF mutation status.
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.62
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.01
    group Description
    Hazard ratio is obtained from the stratified Pike estimator.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Comment
    A hazard ratio \<1 indicates a lower risk with dabrafenib + trametinib compared with Placebo.
    non Inferiority Type
    SUPERIORITY
    p Value
    0.063
    param Type
    Hazard Ratio, log
    param Value
    0.80
    statistical Comment
    Hazard Ratio and p-value from stratified log-rank test are adjusted for randomized strata: Disease stage and BRAF mutation status.
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. comment
        N/A: Not Estimable due to number of events censored
        group Id
        OG000
        lower Limit
        120.7
        upper Limit
        NA
        value
        NA
      2. comment
        N/A: Not Estimable due to number of events censored
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      438
    2. group Id
      OG001
      value
      432
    units
    Participants
description
Overall Survival (OS) was defined as the interval from randomization to the date of death, irrespective of the cause of death. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.
dispersion Type
Full Range
groups
  1. description
    Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
    id
    OG000
    title
    Dabrafenib and Trametinib Combination Therapy
  2. description
    Subjects received matching placebos orally for 12 months
    id
    OG001
    title
    Dabrafenib and Trametinib Placebos
param Type
MEDIAN
population Description
Intent-to-Treat (ITT) Population
reporting Status
POSTED
time Frame
Approximately 10 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice